ROWLAND LLOYD A 4
4 · CytomX Therapeutics, Inc. · Filed Sep 22, 2023
Insider Transaction Report
Form 4
ROWLAND LLOYD A
General Counsel
Transactions
- Sale
Common Stock
2023-09-22$1.30/sh−5,486$7,135→ 80,609 total - Award
Common Stock
2023-09-20+15,000→ 86,095 total
Footnotes (3)
- [F1]Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
- [F2]Includes 41,875 restricted stock units.
- [F3]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.